Sara Taranto
Brescia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Corrigendum to "FGF/FGFR inhibitors downmodulate c-Myc oncoprotein and hamper the growth of adrenocortical carcinoma" [Biomed. Pharmacother. 192 (2025) 118677].
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 23, 2025
FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 18, 2025
Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival.
Journal: Cell death & disease
Published: March 06, 2025
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 19, 2024
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity.
Journal: Pharmacological research
Published: December 20, 2023
FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer.
Journal: Cancer letters
Published: August 03, 2021
Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells.
Journal: Cancers
Published: April 02, 2021
Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.
Journal: International journal of molecular sciences
Published: November 02, 2020
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma.
Journal: European journal of medicinal chemistry
Published: October 21, 2020
NEAT1: a multifaceted long non-coding RNA in multiple myeloma.
Journal: Haematologica
Published: September 10, 2020
β-Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease.
Journal: International journal of molecular sciences
Published: October 25, 2019
Last Updated: 09/26/2026